Prescription drug · ANDA
Cabergoline NDC 50090-7642
Cabergoline .5 mg/1 · Tablet · Oral · A-S Medication Solutions
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50090-7642-0 | 50090764200 | 8 TABLET in 1 BOTTLE (50090-7642-0)Marketed from Aug 26, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cabergoline
- Generic name (nonproprietary)
- cabergoline
- Active ingredients
- Cabergoline — .5 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- A-S Medication Solutions
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 218618
- Marketing start
- Listing expires
- Other FDA classes
- Ergolines (Chemical structure)
- Identifiers
- Product ID 50090-7642_f0d4a3cf-7de2-4959-b8b6-a2753d0deb15SPL ID f0d4a3cf-7de2-4959-b8b6-a2753d0deb15SPL set ID 9405c116-4a77-4e14-9ab8-25e899595cdfRxCUI 199703UNII LL60K9J05T
- Pharmacologic class
- Ergot Derivative
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450090764200followed by a unit qualifier and the quantityPackage 50090-7642-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 218618
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Cabergoline | Cabergoline .5 mg/1 | TabletOral | Amneal Pharmaceuticals NY LLC | 69238-2693 |